DDInter1266 DDInter856
Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of clinical situations requiring analgesia. Naproxen is available in both immediate and delayed release formulations, in combination with sumatriptan to treat migraines, and in combination with esomeprazole to lower the risk of developing gastric ulcers.
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated heparin is more specific than LMWH for thrombin. Furthermore, the effects of UH can typically be reversed by using protamine sulfate.
Naproxen {u} (Compound) resembles {v} (Compound) Suprofen
Naproxen {u} (Compound) resembles {v} (Compound) Oxybenzone
Naproxen {u} (Compound) treats {v} (Disease) gout
Naproxen {u} (Compound) binds {v} (Gene) CYP2C9
Naproxen {u} (Compound) upregulates {v} (Gene) FAM63A
Naproxen {u} (Compound) palliates {v} (Disease) osteoarthritis
Naproxen {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Naproxen {u} (Compound) downregulates {v} (Gene) TXLNA
Naproxen {u} (Compound) causes {v} (Side Effect) Muscular weakness
Naproxen {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) PTGS2
Naproxen (Compound) resembles Suprofen (Compound)
Naproxen (Compound) resembles Oxybenzone (Compound)
Naproxen (Compound) treats gout (Disease)
Naproxen (Compound) binds CYP2C9 (Gene)
Naproxen (Compound) upregulates FAM63A (Gene)
Naproxen (Compound) palliates osteoarthritis (Disease)
Naproxen (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class)
Naproxen (Compound) downregulates TXLNA (Gene)
Naproxen (Compound) causes Muscular weakness (Side Effect)
Naproxen (Compound) binds PTGS2 (Gene) and Naproxen (Compound) upregulates PTGS2 (Gene)